RYZODEG 70 Drug Profile
✉ Email this page to a colleague
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for RYZODEG 70 Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for RYZODEG 70 Derived from DrugPatentWatch Analysis and Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2034-08-21 | DrugPatentWatch analysis and company disclosures |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2037-12-14 | DrugPatentWatch analysis and company disclosures |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2037-11-01 | DrugPatentWatch analysis and company disclosures |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2037-12-21 | DrugPatentWatch analysis and company disclosures |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2039-08-27 | DrugPatentWatch analysis and company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for RYZODEG 70 Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2039-06-21 | Patent claims search |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2033-10-09 | Patent claims search |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Start Trial | 2032-10-25 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for RYZODEG 70
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 235735 | ⤷ Start Trial |
| Japan | 5903119 | ⤷ Start Trial |
| European Patent Office | 2303227 | ⤷ Start Trial |
| Norway | 20061026 | ⤷ Start Trial |
| South Korea | 101534422 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RYZODEG 70
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 13C0035 | France | ⤷ Start Trial | PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121 |
| C02107069/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: INSULIN DEGLUDEC; SWISSMEDIC-ZULASSUNG, 62562 12.03.2013 |
| 300597 | Netherlands | ⤷ Start Trial | PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001 20130123 |
| 92226 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121 |
| 35/2013 | Austria | ⤷ Start Trial | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC AND INSULIN ASPART UND BELIEBIGE ZN2+-KOMPLEXE DAVON; REGISTRATION NO/DATE: EU/1/12/806/001, EU/1/12/806/004, EU/1/12/806/005, EU/1/12/806/007, EU/1/12/806/008 (MITTEILUNG) 20180123 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
